Better Identification of Cognitive Decline With Interleukin-2 Than With Amyloid and Tau Protein Biomarkers in Amnestic Mild Cognitive Impairment

Better Identification of Cognitive Decline With Interleukin-2 Than With Amyloid and Tau Protein Biomarkers in Amnestic Mild Cognitive Impairment

The rate of cognitive decline among patients with amnestic mild cognitive impairment (aMCI) varies, and it is thus crucial to accurately predict the probability of cognitive deterioration in patients with MCI. We compared the potential of cytokines with amyloid beta (Aβ) and tau biomarkers for predi...

Full description

Bibliographic Details
Main Authors: Chih-Sung Liang, Chia-Lin Tsai, Guan-Yu Lin, Jiunn-Tay Lee, Yu-Kai Lin, Che-Sheng Chu, Yueh-Feng Sung, Chia-Kuang Tsai, Ta-Chuan Yeh, Hsuan-Te Chu, Ming-Wei Su, Fu-Chi Yang
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-05-01
Series:Frontiers in Aging Neuroscience
Subjects:
predictive biomarkers
Alzheimer’s disease
amnestic mild cognitive impairment
interleukin-2
beta amyloid
tau protein
Online Access:https://www.frontiersin.org/articles/10.3389/fnagi.2021.670115/full

Internet

https://www.frontiersin.org/articles/10.3389/fnagi.2021.670115/full

Similar Items